Detalhe da pesquisa
1.
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction.
Cancer Cell Int
; 22(1): 286, 2022 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36123697